Navigation Links
Dr. Renu Razdan of Max Neeman International Appointed Vice Chairman, ACRO India
Date:12/5/2013

RESEARCH TRIANGLE PARK, N.C., Dec. 5, 2013 /PRNewswire/ -- The Association of Contract Research Organizations [ACRO] India has appointed Max Neeman's Chief Operating Officer, Dr. Renu Razdan as Vice Chairman. The appointment is effective immediately with key responsibility to create and strengthen the network with regulatory agencies, law makers and scientific community in India.

Max Neeman, a leading Indian provider of clinical research services to the pharmaceutical, biotech and medical device industry for over 10 years, promoted Dr. Razdan to COO in 2009. Prior to joining the company, she worked at Ranbaxy Laboratories Limited as Senior Manager Business Development then Head of Exports, and has also worked with Transasia Biomedicals and HPCL Systems.

Dr. Razdan holds a PhD in Biochemistry from German Cancer Research Centre (DKFZ), Heidelberg, Germany and has been featured as a prominent female achiever in the Life Sciences community; November 2010 issue of 'BioSpectrum India' life science journal.

When asked what she hopes to achieve, Dr. Razdan's response was twofold: 1) to strengthen the channels of communication between industry, regulators and other stakeholders for drug development in India 2) focus on promoting India as a place where good drug development research takes place, despite recent challenges.

About Max Neeman International
'Max Neeman' is a leading Asia-Pacific CRO with India expertise and expanded capabilities into N. America and Europe. Since 2001, the company has provided clinical research services for the successful conduct of drug and device trials in compliance with ICH GCP standards. The company is ISO 9001:2008 certified for monitoring, site management and data management with over >400 employees, 245 active sites in various therapeutic areas and 310 trials awarded. Data Management services alone have touched 60 countries. For more information contact Donald Swankie, Vice President USA:  919.424.3345, donald.swankie@neeman-medical.com or go to www.neeman-medical.com.

About ACRO
ACRO is an independent, non-profit organization with a global perspective. ACRO India, founded and registered in India in Feb 2005, has been formed under the aegis of Confederation of Indian Industry (CII) for bringing all CRO's operating in India on one common platform. With its vision of establishing India as a global sourcing hub for Contract Research, ACRO is used to promote quality research, uphold ethics, share best practices, promote synergies amongst members, to deliberate and act upon common concerns, especially with regards to Indian regulations and industry environment.


'/>"/>
SOURCE Max Neeman International
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. UV Flu Technologies Expands Its International Footprint
2. Elsevier Supports International Crisis Aid Through Pillars of Hope Campaign
3. International Attendance for Networking and Education at Informex Beyond Manufacturing
4. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
5. Experts Launch the Alliance for Fertility Preservation at the International Society for Fertility Preservations 2nd World Congress
6. First Free-Standing International Mesothelioma Research Laboratory Opens in Los Angeles
7. PAREXEL International to Present at J.P. Morgan Healthcare Conference
8. Elsevier Launches Bilingual International Nursing Skill Training and Management Platform: NursingChina.com
9. Senior Management of NeoStem and Its Subsidiaries Invited to Speak at Seventh International Conference on Cell Therapy for Cardiovascular Disease
10. First Product Candidate Moving Toward Commercialization as Result of Novus International and Verenium Collaboration
11. BioRestorative Therapies to Present at 7th International Conference on Cell Therapy for Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... March 21, 2017 , ... Proper glycosylation ... on the desired increase and/or decrease in antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity, ... of therapeutic antibodies. , To meet this demand, the team at SCIEX ...
(Date:3/22/2017)... , ... March 21, 2017 , ... Functional near-infrared spectroscopy ... is being explored as a way to track the brain’s response to acute pain ... activation by cold pressor test ,” published today in the journal Neurophotonics , ...
(Date:3/22/2017)... 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), a ... significant unmet medical needs, today announced Alexey ... present at the 5th Annual Cancer BioPartnering & ... to present to and meet with thought leaders ... companies as well as institutional investors. This event ...
(Date:3/20/2017)... Diego, CA (PRWEB) , ... March 20, 2017 ... ... novel therapies for gastrointestinal (GI) disorders, today announced that it has entered into ... (NRG-4) for therapies in inflammatory bowel disease including Necrotizing Enterocolitis (rare orphan disease) ...
Breaking Biology Technology:
(Date:3/16/2017)... Germany , March 16, 2017 CeBIT 2017 - Against identity ... Continue Reading ... Used combined in one project, multi-biometric solutions provide ... Used ... Systems) ...
(Date:3/9/2017)... Australia , March 9, 2017 /PRNewswire/ ... at the prestigious World Lung Imaging Workshop at the ... Fouras , was invited to deliver the latest data ... This globally recognised event brings together leaders at the ... latest developments in lung imaging. "The ...
(Date:3/7/2017)... March 7, 2017 Brandwatch , the leading social ... The Prince,s Trust to uncover insights to support its reporting, ... The UK,s leading youth charity will be using Brandwatch ... and get a better understanding of the topics and issues that ... ...
Breaking Biology News(10 mins):